Kezar investors get cash now and future drug upside in Aurinia deal Aurinia plans to start its tender offer by Apr. 13, with closing expected in Q2 2026. Tang Capital, which owns about 9%, agreed to support the deal.

#KZR #AUPH Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

www.stocktitan.net/news/KZR/aurinia-pharmac...

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences Enodia Therapeutics acquired Kezar Life Sciences' preclinical Sec61 assets to deepen Sec61 selectivity insights and accelerate development of Enodia's PARIS programs.Transaction includes an $1 million upfront, potential milestone payments totaling up to $127 million, and tiered royalties on net sales, broadening Enodia's proteomics, Cryo-EM, and cell‑line datasets for rational small‑molecule design.

#KZR Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences

www.stocktitan.net/news/KZR/enodia-therapeu...

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis Kezar Life Sciences (Nasdaq:KZR) announced the FDA Division of Hepatology and Nutrition granted a Type C meeting in Q1 2026 to discuss development of zetomipzomib, a selective immunoproteasome inhibitor, for autoimmune hepatitis (AIH).Kezar submitted pharmacokinetic and hepatic safety analyses from prior trials to support a proposed global randomized Phase 2b study and parallel AIH and hepatic impairment assessments, plus additional safety data and an updated risk‑mitigation plan intended to address the prior 48‑hour in‑unit monitoring requirement. The company also noted retention of TD Cowen for a strategic review that included workforce reductions and cost‑conservation measures.

#KZR Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

www.stocktitan.net/news/KZR/kezar-life-scie...

Grafa Grafa is the world's most powerful AI market screener for shares, crypto and forex. Track the ASX200, Dow Jones, NYSE, Nasdaq, crypto, and company share prices. Research finance terms and uncover hot stocks

Kalamazoo Resources ( #KZR ) has released " KZR Share Purchase Plan Opens " on Fri 09 Jan at 12:21 AEST #today #tax #Pilbara #trading #Mining

Grafa Grafa is the world's most powerful AI market screener for shares, crypto and forex. Track the ASX200, Dow Jones, NYSE, Nasdaq, crypto, and company share prices. Research finance terms and uncover hot stocks

Kalamazoo Resources ( #KZR ) has released " Kalamazoo Launches $8 million Placement & $2 million SPP " on Wed 24 Dec at 09:33 AEST #Pilbara #trading #Gold #Australia #media

#KZR Kezar Life Sciences Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/KZR/kezar-life-scie...

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 Kezar Life Sciences, Inc., a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the completed Phase 2 a PORTOLA clinical trial in patients with autoimmune hepatitis at The Liver Meeting 2025 held by the American Association for the...

#KZR Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

www.stocktitan.net/news/KZR/kezar-life-scie...

Kalamazoo Resources share price Kalamazoo Resources (ASX:KZR) is an asset listed on the ASX, and part of the Materials sector. Grafa’s asset page shows Kalamazoo Resources’s share price, chart

Kalamazoo Resources ( #KZR ) has released " Significant Update - Gold Resource & Exploration Target " on Mon 20 Oct at 09:03 AEST #Inflation #Pilbara #trading #Mining #Gold

Just In: ( NASDAQ: #KZR ) KZR Price Target Alert: $5.00. Issued by Wells Fargo

Trade Alerts, Thursday October 16, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Oct 16th - #WBUY #TOYO #YDKG #UROY #SATL #OCCI #LOOP #KZR #HYPR #GBIO #FOSL #CCII #ARTV #IIIN - More: crystalequityresearch.com/trade-alerts... - #smallcap

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives Kezar Life Sciences (Nasdaq: KZR) announced it is exploring strategic alternatives and retained TD Cowen to support the review while implementing a restructuring and workforce reduction. The FDA canceled a planned Type C meeting about a potential registrational zetomipzomib study in autoimmune hepatitis (AIH) and requested a stand-alone hepatic impairment pharmacokinetic study that would delay AIH trials by ~2 years. The FDA also requires 48-hour in‑unit monitoring for future zetomipzomib trials. Kezar reported ~$90.2M in cash, cash equivalents and marketable securities as of September 30, 2025. Final PORTOLA data will be presented on November 10, 2025 at The Liver Meeting.

#KZR Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

www.stocktitan.net/news/KZR/kezar-life-scie...

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update Kezar Life Sciences (Nasdaq: KZR) reported key developments in Q2 2025, highlighting progress with its lead drug candidate zetomipzomib. The FDA removed the partial clinical hold on the PORTOLA Phase 2a trial for autoimmune hepatitis (AIH), where the drug showed promising results with 36% of treated patients achieving complete biochemical response versus 0% in placebo group.The company's financial position shows $100.8 million in cash and equivalents as of June 30, 2025, down from $132.2 million at end-2024. Q2 2025 net loss improved to $13.7 million ($1.87 per share) compared to $21.5 million in Q2 2024, with reduced R&D expenses of $9.6 million and G&A expenses of $5.0 million.Kezar has submitted a Type C meeting request with the FDA for Q4 2025 to discuss zetomipzomib's development plan in AIH, and the PORTOLA data has been selected for oral presentation at The Liver Meeting® 2025.

#KZR Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/KZR/kezar-life-scie...

Kalamazoo Resources share price Kalamazoo Resources (ASX:KZR) is an asset listed on the ASX, and part of the Materials sector. Grafa’s asset page shows Kalamazoo Resources’s share price, chart

Kalamazoo Resources ( #KZR ) has released " Kalamazoo to Progress 1.44Moz Ashburton Gold Project " on Tue 29 Jul at 09:35 AEST #today #Pilbara #trading #Mining #Gold

Kevin & Zach React Welcome to Kevin & Zach React! One of the two shows of the Ryan Ripken Media Network. Based out of Baltimore, we are LIVE after every Orioles and Ravens games. Come join us for all the real raw reac...

Live after EVERY #Orioles game, win or lose. Raw reaction and sometimes therapy! Subscribe and hit all notifications to join us tonight!
#KZR #RRS
youtube.com/@kevinzachre...

Kalamazoo Resources share price Kalamazoo Resources (ASX:KZR) is an asset listed on the ASX, and part of the Materials sector. Grafa’s asset page shows Kalamazoo Resources’s share price, chart

Kalamazoo Resources ( #KZR ) has released " Trading Halt " on Fri 25 Jul at 09:26 AEST #trading #Gold #media #ltd #ASX

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Wed Jul 16th - #ONCO #NXL #UFG #REBN #MLEC #ISPC #NWTN #PEW #ECX #IKNA #KZR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stock with strong volume gains, Tue Jul 15th- #LSTA #KZR #IKNA #HTOO #DXPE #CMBM #CELU #BWEN #ADAG #ZKIN #XAGE #UCL #RAPT #MSGM #MNY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis Kezar Life Sciences (Nasdaq: KZR) announced that the FDA has lifted the partial clinical hold on its completed PORTOLA Phase 2a trial of zetomipzomib for autoimmune hepatitis (AIH). The decision follows the FDA's review of a comprehensive safety assessment of the zetomipzomib program.While development in lupus nephritis (LN) remains suspended, Kezar has received recommendations from the Independent Data Monitoring Committee (IDMC) regarding future LN clinical trials. The company plans to request the FDA lift the clinical hold for zetomipzomib in LN based on these recommendations and internal safety data analysis.

#KZR Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

www.stocktitan.net/news/KZR/kezar-life-scie...

Planefence ICAO: 4BCDE4
Flt: SXS4AH SUNEXPRESS DUS - KZR
First seen: 2025-05-23 13:14:07 CEST
Min Alt: 6992 m AGL
Min Dist: 34.87 km
adsb aboveFRL EHLW - adsbexchange

First Successful AIH Treatment Trial in 30 Years: Kezar's Drug Shows Promising Results in Autoimmune Hepatitis Novel drug achieves complete response in treatment-resistant liver disease patients. First major AIH treatment advance in 3 decades. See detailed trial outcomes.

#KZR Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/KZR/kezar-life-scie...

Kalamazoo Resources share price Kalamazoo Resources (ASX:KZR) is an asset listed on the ASX, and part of the Materials sector. Grafa’s asset page shows Kalamazoo Resources’s share price, chart

Kalamazoo Resources ( #KZR ) has released " Trading Halt " on Tue 29 Apr at 09:25 AEST #trading #media #ASX #TradingHalt #SEC

YouTube Share your videos with friends, family, and the world

Live reaction to #Baltimore #Ravens win #KZR #KevinAndZachReact #RyanRipkenMediaEmpire

www.youtube.com/live/Qb_JYOB...

BREAKING NEWS: ( NASDAQ: #KZR ) Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

#StockMarket #News